| 論文種別 | 原著(症例報告除く) |
| 言語種別 | 英語 |
| 査読の有無 | その他(不明) |
| 表題 | Comparison of cisplatin-based versus standard preoperative chemotherapy in patients with operable triple-negative breast cancer: propensity score matching and inverse probability of treatment weighting analysis. |
| 掲載誌名 | 正式名：Breast cancer research and treatment 略 称：Breast Cancer Res Treat ISSNコード：15737217/01676806 |
| 巻・号・頁 | 204(2),pp.261-275 |
| 著者・共著者 | Ayane Yamaguchi, Kosuke Kawaguchi, Kana Kawanishi, Yurina Maeshima, Akiyoshi Nakakura, Tatsuki R Kataoka, Sachiko Takahara, Shunsaku Nakagawa, Atsushi Yonezawa, Masahiro Takada, Masahiro Kawashima, Nobuko Kawaguchi-Sakita, Takeshi Kotake, Eiji Suzuki, Hanako Shimizu, Masae Torii, Satoshi Morita, Hiroshi Ishiguro, Masakazu Toi |
| 発行年月 | 2024/04 |
| 概要 | PURPOSE:The efficacy of carboplatin is non-equivalent to that of cisplatin (CDDP) for various tumor types in curative settings. However, the role of CDDP in operable triple-negative breast cancer (TNBC) patients remains unknown. We conducted a multicenter observational study to examine the effects of CDDP added to preoperative chemotherapy in patients with TNBC.METHODS:This retrospective study consecutively included previously untreated patients with stage I-III TNBC treated with preoperative chemotherapy with or without CDDP. The primary endpoint was distant disease-free survival (DDFS). Propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) were used to minimize confounding biases in comparisons between the two groups.RESULTS:A total of 138 patients were enrolled in the study. Of these, 52 were in the CDDP group and 86 in the non-CDDP group. DDFS was significantly better in the CDDP group than in the non-CDDP group (unadjusted hazard ratio (HR) 0.127 and p < 0.001, PSM HR 0.141 and p < 0.003, IPTW HR 0.123 and p = < 0.001). Furthermore, among the patients with residual cancer burden (RCB) class II/III, DDFS was better in the CDDP group than in the non-CDDP group (unadjusted HR 0.192 and p = 0.013, PSM HR 0.237 and p = 0.051, IPTW HR 0.124 and p = 0.059).CONCLUSION:Our study showed that CDDP-containing regimens achieved favorable prognoses in patients with operable TNBC, especially for the RCB class II/III population. Confirmative studies are warranted to elucidate the role of CDDP in TNBC treatment. |
| DOI | 10.1007/s10549-023-07163-z |
| PMID | 38123790 |